Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjögren's syndrome: Data from a placebo-controlled clinical trial

Annals of the Rheumatic Diseases

Volumn 72, Issue 1, 2013, Pages 146-148

  Pollard, Rodney P E ^a   Abdulahad, Wayel H ^a   Vissink, Arjan ^a   Hamza, Nishath ^a   Burgerhof, Johannes G M ^a   Meijer, Jiska M ^a   Visser, Annie ^a   Huitema, Minke G ^a   Spijkervet, Fred K L ^a   Kallenberg, Cees G M ^a   Bootsma, Hendrika ^a   Kroese, Frans G M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APRIL PROTEIN; B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR RECEPTOR; IMMUNOGLOBULIN G; RITUXIMAB;

BINDING AFFINITY; BINDING SITE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LETTER; MOLECULAR DYNAMICS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SJOEGREN SYNDROME; UPREGULATION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; B-CELL ACTIVATING FACTOR; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; SJOGREN'S SYNDROME; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 84871038633     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202071     Document Type: Letter

References (10)

1. Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjögren's syndrome. A randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:960-8.
2. Schneider P. The role of APRIL and BAFF in lymphocyte activation. Curr Opin Immunol 2005;17:282-9. (Pubitemid 40692663)
3. Lavie F, Miceli-Richard C, Ittah M, et al. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis 2007;66:700-3. (Pubitemid 46707145)
4. Pers J, Devauchelle V, Daridon C, et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. Arthritis Rheum 2007;56:1464-77. (Pubitemid 46764075)
5. Ota M, Duong BH, Torkamani A, et al . Regulation of the B cell receptor repertoire and self-reactivity by BAFF. J Immunol 2010;185:4128-36.
6. Lesley R, Xu Y, Kalled SL, et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004;20:441-53. (Pubitemid 38482122)
7. Moreaux J, Legouffe E, Jourdan E, et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004;103:3148-57. (Pubitemid 38451693)
8. Laabi Y, Gras MP, Brouet JC, et al. The BCMA gene, preferentially expressed during B-lymphoid maturation, is bidirectionally transcribed. Nucleic Acids Res 1994;22:1147-54. (Pubitemid 24162116)
9. Vallerskog T, Heimburger M, Gunnarsson I, et al. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2006;8:R167.
10. Nagel A, Podstawa E, Eickmann M, et al. Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris. J Invest Dermatol 2009;129:2202-10.